Ozmosi | Albusomatropin Drug Profile

Product Description

Human serum albumin fused to the N-terminus of growth hormone (Sourced from: https://chem.nlm.nih.gov/chemidplus/rn/1613273-96-3)

Mechanisms of Action: Growth Hormone Analogue

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Teva
Company Location: Europe
Company Founding Year: 1901
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Hypopituitarism|Dwarfism, Pituitary|Deficiency Diseases|Pituitary Diseases

Phase 2: Deficiency Diseases|Hypopituitarism|Dwarfism, Pituitary|Pituitary Diseases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT02092077	TV1106-IMM-20001	P2	Terminated	Dwarfism, Pituitary\|Hypopituitarism	2016-04-30	2019-03-20	Treatments
2013-004468-69	2013-004468-69	P2	Terminated	Hypopituitarism	2016-04-29	2022-03-13	Treatments
2012-004975-37	2012-004975-37	P2	Completed	Hypopituitarism	2015-06-22	2025-06-25	Treatments
NCT01811576	TV1106-GHD-201	P2	Completed	Deficiency Diseases\|Dwarfism, Pituitary\|Pituitary Diseases\|Hypopituitarism	2013-08-05	2021-12-11	Primary Endpoints
2014-002736-13	2014-002736-13	P3	Terminated	Hypopituitarism	2017-08-19	2022-03-13	Treatments
NCT02410356	TV1106-IMM-30022	P3	Terminated	Deficiency Diseases\|Dwarfism, Pituitary\|Pituitary Diseases\|Hypopituitarism	2016-02-29	2021-12-11	Primary Endpoints\|Treatments
NCT02410343	TV1106-IMM-30021	P3	Terminated	Hypopituitarism	2015-12-31	2022-01-22	Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments
2014-003796-32	2014-003796-32	P3	Terminated	Hypopituitarism	2015-12-18	2022-03-13

Recent News Events

Date	Type	Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Albusomatropin

Alternative Names: albusomatropin, tv-1106, tv1106, tv 1106 Clinical Status: Inactive Latest Update: 2022-01-21 Latest Update Note: Clinical Trial Update